Changes in interleukin-1 signal modulators induced by 3,4-methylenedioxymethamphetamine (MDMA): Regulation by CB2 receptors and implications for neurotoxicity

Journal of Neuroinflammation

Volumn 8, Issue , 2011, Pages

  Torres, Elisa ^a   Gutierrez Lopez, Maria D ^a   Mayado, Andrea ^a   Rubio, Ana ^a   O'Shea, Esther ^a   Colado, Maria I ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; CANNABINOID 2 RECEPTOR; IMMUNOGLOBULIN G; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR TYPE I; SEROTONIN TRANSPORTER; INTERLEUKIN 1 RECEPTOR; PSYCHEDELIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE RELEASE; FRONTAL CORTEX; HYPERTHERMIA; HYPOTHALAMUS; MALE; MICROGLIA; NEUROTOXICITY; NONHUMAN; PERIKARYON; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; ANIMAL; BODY TEMPERATURE; BRAIN; CYTOLOGY; DRUG EFFECT; HISTOLOGY; METABOLISM; NERVE CELL; PHYSIOLOGY;

ANIMALS; BODY TEMPERATURE; BRAIN; HALLUCINOGENS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEURONS; RATS; RECEPTOR, CANNABINOID, CB2; RECEPTORS, INTERLEUKIN-1; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SIGNAL TRANSDUCTION;

EID: 79956044547     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-8-53     Document Type: Article

References (59)

1. Sharkey J, McBean DE, Kelly PA. Alterations in hippocampal function following repeated exposure to the amphetamine derivative methylenedioxymethamphetamine ("Ecstasy"). Psychopharmacology 1991, 105:113-118. 10.1007/BF02316872, 1684057.
2. Hewitt KE, Green AR. Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ('Ecstasy') to rats. Neuropharmacology 1994, 33:1589-1595. 10.1016/0028-3908(94)90134-1, 7539115.
3. Colado MI, O'Shea E, Granados R, Murray TK, Green AR. In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine. Br J Pharmacol 1997, 121:889-900. 10.1038/sj.bjp.0701213, 1564770, 9222545.
4. Sanchez V, Camarero J, Esteban B, Peter MJ, Green AR, Colado MI. The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain. Br J Pharmacol 2001, 134:46-57. 10.1038/sj.bjp.0704230, 1572928, 11522596.
5. O'Shea E, Orio L, Escobedo I, Sanchez V, Camarero J, Green AR, Colado MI. MDMA-induced neurotoxicity: long-term effects on 5-HT biosynthesis and the influence of ambient temperature. Br J Pharmacol 2006, 148:778-785. 1617070, 16770327.
6. O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 1988, 8:2788-2803.
7. Orio L, O'Shea E, Sanchez V, Pradillo JM, Escobedo I, Camarero J, Moro MA, Green AR, Colado MI. 3,4-Methylenedioxymethamphetamine increases interleukin-1beta levels and activates microglia in rat brain: studies on the relationship with acute hyperthermia and 5-HT depletion. J Neurochem 2004, 89:1445-1453. 10.1111/j.1471-4159.2004.02443.x, 15189347.
8. O'Shea E, Sanchez V, Orio L, Escobedo I, Green AR, Colado MI. 3,4-Methylenedioxymethamphetamine increases pro-interleukin-1beta production and caspase-1 protease activity in frontal cortex, but not in hypothalamus, of Dark Agouti rats: role of interleukin-1beta in neurotoxicity. Neuroscience 2005, 135:1095-1105. 10.1016/j.neuroscience.2005.06.084, 16165281.
9. Torres E, Gutierrez-Lopez MD, Borcel E, Peraile I, Mayado A, O'Shea E, Colado MI. Evidence that MDMA ('ecstasy') increases cannabinoid CB2 receptor expression in microglial cells: role in the neuroinflammatory response in rat brain. J Neurochem 2010, 113:67-78. 10.1111/j.1471-4159.2010.06578.x, 20067581.
10. Blamire AM, Anthony DC, Rajagopalan B, Sibson NR, Perry VH, Styles P. Interleukin-1b-induced changes in blood-brain barrier permeability, apparent diffusion coefficient, and cerebral blood volume in the rat brain: A magnetic resonance study. J Neurosci 2000, 20:8153-8159.
11. Greenwood J. Mechanisms of blood-brain barrier breakdown. Neuroradiology 1991, 33:95-100. 10.1007/BF00588242, 2046916.
12. Heo JH, Han SW, Lee SK. Free radicals as triggers of brain edema formation after stroke. Free Radic Biol Med 2005, 39:51-70. 10.1016/j.freeradbiomed.2005.03.035, 15925278.
13. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57:178-201. 10.1016/j.neuron.2008.01.003, 18215617.
14. O'Shea E, Granados R, Esteban B, Colado MI, Green AR. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology 1998, 37:919-926. 10.1016/S0028-3908(98)00029-X, 9776387.
15. Colado MI, Esteban B, O'Shea E, Granados R, Green AR. Studies on the neuroprotective effect of pentobarbitone on MDMA-induced neurodegeneration. Psychopharmacology 1999, 142:421-425. 10.1007/s002130050908, 10229068.
16. Arevalo-Martín A, Vela JM, Molina-Holgado E, Borrell J, Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 2003, 23:2511-2516.
17. Chin CL, Tovcimak AE, Hradil VP, Seifert TR, Hollingsworth PR, Chandran P, Zhu CZ, Gauvin D, Pai M, Wetter J, Hsieh GC, Honore P, Frost JM, Dart MJ, Meyer MD, Yao BB, Cox BF, Fox GB. Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI. Br J Pharmacol 2008, 153:367-379. 10.1038/sj.bjp.0707506, 2219521, 17965748.
18. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254. 10.1016/0003-2697(76)90527-3, 942051.
19. König JFR, Klippel RA. The Rat Brain. A Stereotaxic Atlas of the Forebrain and Lower Parts of the Brain Stem. 1963, New York, Robert E Krieger Publishing Co Inc.
20. Baldwin HA, Colado MI, Murray TK, De Souza RJ, Green AR. Striatal dopamine release in vivo following neurotoxic doses of methamphetamine and effect of the neuroprotective drugs, chlormethiazole and dizocilpine. Br J Pharmacol 1993, 108:590-596. 1908047, 8467354.
21. Lowry OH, Rosebrough NJ, Farr AL, Randal RJ. Protein measurement with the folin phenol reagent. J Biol Chemistry 1951, 193:265-275.
22. Arend WP. The balance between IL-1 and IL-1ra in disease. Cytokine Growth Factor Rev 2002, 13:323-340. 10.1016/S1359-6101(02)00020-5, 12220547.
23. Eriksson C, Zou LP, Ahlenius S, Winblad B, Schultzberga M. Inhibition of kainic acid induced expression of interleukin-1b and interleukin-1 receptor antagonist mRNA in the rat brain by NMDA receptor antagonists. Molecular Brain Res 2000, 85:103-113.
24. Hailer NP, Vogt C, Korf HW, Dehghani F. Interleukin-1beta exacerbates and interleukin-1 receptor antagonist attenuates neuronal injury and microglial activation after excitotoxic damage in organotypic hippocampal slice cultures. Eur J Neurosci 2005, 21:2347-2360. 10.1111/j.1460-9568.2005.04067.x, 15932594.
25. Vroon A, Drukarch B, Bol JG, Cras P, Brevé JJ, Allan SM, Relton JK, Hoogland PV, Van Dam AM. Neuroinflammation in Parkinson's patients and MPTP-treated mice is not restricted to the nigrostriatal system: microgliosis and differential expression of interleukin-1 receptors in the olfactory bulb. Exp Gerontol 2007, 42:762-771. 10.1016/j.exger.2007.04.010, 17592750.
26. van Deuren M, van der Ven-Jongekrijg J, Vannier E, van Dalen R, Pesman G, Bartelink AK, Dinarello CA, van der Meer JW. The pattern of interleukin-1beta (IL-1beta) and its modulating agents IL-1 receptor antagonist and IL-1 soluble receptor type II in acute meningococcal infections. Blood 1997, 90:1101-1108.
27. Relton JK, Rothwell NJ. Interleukin-1 receptor antagonist inhibits ischaemic and excitotoxic neuronal damage in the rat. Brain Res Bull 1992, 29:243-246. 10.1016/0361-9230(92)90033-T, 1388088.
28. Loddick SA, Rothwell NJ. Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat. J Cereb Blood Flow Metab 1996, 16:932-940.
29. Lawrence CB, Allan SM, Rothwell NJ. Interleukin-1beta and the interleukin-1 receptor antagonist act in the striatum to modify excitotoxic brain damage in the rat. Eur J Neurosci 1998, 10:1188-1195. 10.1046/j.1460-9568.1998.00136.x, 9753187.
30. Jones NC, Prior MJ, Burden-Teh E, Marsden CA, Morris PG, Murphy S. Antagonism of the interleukin-1 receptor following traumatic brain injury in the mouse reduces the number of nitric oxide synthase-2-positive cells and improves anatomical and functional outcomes. Eur J Neurosci 2005, 22:72-78. 10.1111/j.1460-9568.2005.04221.x, 16029197.
31. Koprich JB, Reske-Nielsen C, Mithal P, Isacson O. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J Neuroinflammation 2008, 5:8. 10.1186/1742-2094-5-8, 2292163, 18304357.
32. Schmid AW, Lynch MA, Herron CE. The effects of IL-1 receptor antagonist on beta amyloid mediated depression of LTP in the rat CA1 in vivo. Hippocampus 2009, 19:670-676. 10.1002/hipo.20542, 19115392.
33. Plata-Salamán CR, Ffrench-Mullen JM. Intracerebroventricular administration of a specific IL-1 receptor antagonist blocks food and water intake suppression induced by interleukin-1 beta. Physiol Behav 1992, 51:1277-1279. 10.1016/0031-9384(92)90321-R, 1386466.
34. Takao T, Culp SG, De Souza EB. Reciprocal modulation of interleukin-1 beta (IL-1 beta) and IL-1 receptors by lipopolysaccharide (endotoxin) treatment in the mouse brain-endocrine-immune axis. Endocrinology 1993, 132:1497-1504. 10.1210/en.132.4.1497, 8462448.
35. Takao T, Nakata H, Tojo C, Kurokawa H, Nishioka T, Hashimoto K, De Souza EB. Regulation of interleukin-1 receptors and hypothalamic-pituitary-adrenal axis by lipopolysaccharide treatment in the mouse. Brain Res 1994, 649:265-270. 10.1016/0006-8993(94)91073-1, 7953641.
36. Sairanen TR, Lindsberg PJ, Brenner M, Sirén AL. Global forebrain ischemia results in differential cellular expression of interleukin-1beta (IL-1beta) and its receptor at mRNA and protein level. J Cereb Blood Flow Metab 1997, 17:1107-1120.
37. Friedman WJ. Cytokines regulate expression of the type 1 interleukin-1 receptor in rat hippocampal neurons and glia. Exp Neurol 2001, 168:23-31. 10.1006/exnr.2000.7595, 11170718.
38. Parnet P, Kelley KW, Bluthé RM, Dantzer R. Expression and regulation of interleukin-1 receptors in the brain. Role in cytokines-induced sickness behavior. J Neuroimmunol 2002, 125:5-14. 10.1016/S0165-5728(02)00022-X, 11960635.
39. Ravizza T, Vezzani A. Status epilepticus induces time-dependent neuronal and astrocytic expression of interleukin-1 receptor type I in the rat limbic system. Neuroscience 2006, 137:301-308. 10.1016/j.neuroscience.2005.07.063, 16289587.
40. French RA, VanHoy RW, Chizzonite R, Zachary JF, Dantzer R, Parnet P, Bluthé RM, Kelley KW. Expression and localization of p80 and p68 interleukin-1 receptor proteins in the brain of adult mice. J Neuroimmunol 1999, 93:194-202. 10.1016/S0165-5728(98)00224-0, 10378883.
41. Pinteaux E, Parker LC, Rothwell NJ, Luheshi GN. Expression of interleukin-1 receptors and their role in interleukin-1 actions in murine microglial cells. J Neurochem 2002, 83:754-763. 10.1046/j.1471-4159.2002.01184.x, 12421347.
42. Wang XF, Huang LD, Yu PP, Hu JG, Yin L, Wang L, Xu XM, Lu PH. Upregulation of type I interleukin-1 receptor after traumatic spinal cord injury in adult rats. Acta Neuropathol 2006, 111:220-228. 10.1007/s00401-005-0016-x, 16456668.
43. Kwon MS, Seo YJ, Lee JK, Lee HK, Jung JS, Jang JE, Park SH, Suh HW. The repeated immobilization stress increases IL-1beta immunoreactivities in only neuron, but not astrocyte or microglia in hippocampal CA1 region, striatum and paraventricular nucleus. Neurosci Lett 2008, 430:258-263. 10.1016/j.neulet.2007.11.006, 18061345.
44. Eriksson C, Van Dam AM, Lucassen PJ, Bol JG, Winblad B, Schultzberg M. Immunohistochemical localization of interleukin-1beta, interleukin-1 receptor antagonist and interleukin-1beta converting enzyme/caspase-1 in the rat brain after peripheral administration of kainic acid. Neuroscience 1999, 93:915-930. 10.1016/S0306-4522(99)00178-5, 10473257.
45. Svenson M, Hansen MB, Heegaard P, Abell K, Bendtzen K. Specific binding of interleukin 1 (IL-1) beta and IL-1 receptor antagonist (IL-1ra) to human serum. High-affinity binding of IL-1ra to soluble IL-1 receptor type I. Cytokine 1993, 5:427-435. 10.1016/1043-4666(93)90032-Z, 8142597.
46. Burger D, Chicheportiche R, Giri JG, Dayer JM. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J Clin Invest 1995, 96:38-41. 10.1172/JCI118045, 185170, 7615809.
47. McMahan CJ, Slack JL, Mosley B, Cosman D, Lupton SD, Brunton LL, Grubin CE, Wignall JM, Jenkins NA, Brannan CI, Copeland NG, Huebner K, Croce CM, Cannizzarro LA, Benjamin D, Dower SK, Spriggs MK, Sims JE. A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types. EMBO J 1991, 10:2821-2832. 452992, 1833184.
48. Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol 2010, 10:89-102.
49. Orio L, Llopis N, Torres E, Izco M, O'Shea E, Colado MI. A study on the mechanisms by which minocycline protects against MDMA ('ecstasy')-induced neurotoxicity of 5-HT cortical neurons. Neurotox Res 2010, 18:187-99. 10.1007/s12640-009-9120-3, 19777321.
50. Ahn KS, Aggarwal BB. Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann N Y Acad Sci 2005, 1056:218-233. 10.1196/annals.1352.026, 16387690.
51. Xie QW, Kashiwabara Y, Nathan C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem 1994, 269:4705-4708.
52. Nadjar A, Bluthé RM, May MJ, Dantzer R, Parnet P. Inactivation of the cerebral NFkappaB pathway inhibits interleukin-1beta-induced sickness behavior and c-Fos expression in various brain nuclei. Neuropsychopharmacology 2005, 30:1492-1499. 10.1038/sj.npp.1300755, 15900319.
53. Aguirre N, Barrionuevo M, Ramírez MJ, Del Río J, Lasheras B. Alpha-lipoic acid prevents 3,4-methylenedioxy-methamphetamine (MDMA)-induced neurotoxicity. Neuroreport 1999, 10:3675-3680. 10.1097/00001756-199911260-00039, 10619665.
54. Sanchez V, Camarero J, O'Shea E, Green AR, Colado MI. Differential effect of dietary selenium on the long-term neurotoxicity induced by MDMA in mice and rats. Neuropharmacology 2003, 44:449-461. 10.1016/S0028-3908(02)00411-2, 12646282.
55. Darvesh AS, Yamamoto BK, Gudelsky GA. Evidence for the involvement of nitric oxide in 3,4-methylenedioxymethamphetamine-induced serotonin depletion in the rat brain. J Pharmacol Exp Ther 2005, 312:694-701.
56. Martiney JA, Litwak M, Berman JW, Arezzo JC, Brosnan CF. Pathophysiologic effect of interleukin-1in the rabbit retina. Am J Pathol 1990, 137:1411-1423. 1877728, 2260629.
57. Jedrzejowska-Szypułka H, Straszak G, Larysz-Brysz M, Karpe J, Marcol W, Olakowska E, Woszczycka-Korczyńska I, Lewin-Kowalik J. Interleukin-1beta plays a role in the activation of peripheral leukocytes after blood-brain barrier rupture in the course of subarachnoid hemorrhage. Curr Neurovasc Res 2010, 7:39-48. 10.2174/156720210790820226, 20158463.
58. Rosenberg GA, Estrada EY, Dencoff JE. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 1998, 29:2189-2195.
59. Sharma HS, Ali SF. Acute administration of 3,4-methylenedioxymethamphetamine induces profound hyperthermia, blood-brain barrier disruption, brain edema formation, and cell injury. Ann N Y Acad Sci 2008, 1139:242-258. 10.1196/annals.1432.052, 18991870.